Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Hydromethylthionine mesylate - TauRx Pharmaceuticals

Next Previous
Search
Drug Profile

Hydromethylthionine mesylate - TauRx Pharmaceuticals

Alternative Names: HMTM; Hydromethylthionine; leuco-methylthioninium; Leuco-methylthioninium-bis(hydromethanesulfonate); LMT-X; LMTM; LMTX; TRx-0237

Latest Information Update: 05 Jul 2024

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator TauRx Pharmaceuticals
  • Class Antidementias; Antiparkinsonians; Diamines; Mesylates; Phenothiazines; Small molecules
  • Mechanism of Action Synuclein inhibitors; Tau protein inhibitors; TDP-43 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Frontotemporal dementia
  • New Molecular Entity Yes

Highest Development Phases

  • Preregistration Alzheimer's disease
  • Phase III Frontotemporal dementia
  • No development reported Parkinson's disease
  • Discontinued Progressive supranuclear palsy

Most Recent Events

  • 01 Jul 2024 Preregistration for Alzheimer's disease in United Kingdom (PO)
  • 06 Feb 2024 TauRx Pharmaceuticals initiates regulatory engagement in the UK and the US for hydromethylthionine mesylate approval
  • 06 Feb 2024 TauRx Pharmaceuticals plans to launch hydromethylthionine mesylate for Alzheimer’s disease

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top